Medline Inc. Class A Common Stock (MDLN)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
MDLN
Medline Inc. Class A Common Stock
$40.08
-1.06%
HEALTHCARE · Cap: $69.65B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$11.59
+14.19%
HEALTHCARE · Cap: $513.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 336903% more annual revenue ($29.14B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 3.3%. MDLN trades at a lower P/E of 34.0x. NNNN earns a higher WallStSmart Score of 52/100 (C-).
MDLN
Buy52
out of 100
Grade: C-
NNNN
Buy52
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 1258.0% YoY
Large-cap with strong market position
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Every $100 of equity generates 24 in profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.3% margin — thin
Elevated debt levels
Trading at 16.8x book value
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Market Cap. Revenue growth of 10.7% demonstrates continued momentum.
Bull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.
Bear Case : NNNN
The primary concerns for NNNN are Price/Book, EPS Growth, Market Cap. A P/E of 78.0x leaves little room for execution misses.
Key Dynamics to Monitor
MDLN profiles as a value stock while NNNN is a growth play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 52/100) and 10.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?